Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1317 - Patient-Derived Xenografts (PDX) Identifies JMJD6 Inhibitor as an Effective Therapeutic Medicine in Colorectal Cancer.

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Feng Ye

Citation

Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246

Authors

F. Ye1, J. You2, L. Xia3, J. Lian3, R. Xiao4, T. Ran4, X. Gao4, J. Li1, X. Zhao1, J. Gao2, H. Lin2, J. Zheng1, W. Liu4

Author affiliations

  • 1 Department Of Medical Oncology, Cancer Hospital, The First Affiliated Hospital of Xiamen University, 361003 - Xiamen/CN
  • 2 Department Of Gastrointestinal Surgery, Cancer Hospital, The First Affiliated Hospital of Xiamen University, 361003 - Xiamen/CN
  • 3 Laboratory Of Cancer Hospital, The First Affiliated Hospital of Xiamen University, 361003 - Xiamen/CN
  • 4 School Of Pharmaceutical Sciences, Fujian Provincial Key Laboratory Of Innovative Drug Target Research, Xiamen University, 361102 - Xiamen/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1317

Background

The Jmjc-domain-containing protein 6 (JMJD6) is a member of JmjC oxygenases that contain both arginine demethylase and lysine hydroxylase activities. Overexpression of JMJD6 has been reported to be associated with the development of various types of cancers, such as breast, lung, liver, and colon cancer. The present study aimed to explore the inhibitory effect of the small-molecule JMJD6 inhibitor named WL8 obtained by virtual screening on the progression of colorectal cancer.

Methods

WL8 was administered to a mouse bearing xenografts of human colorectal cancer tissue, once every 7 days for 3 times. We analyzed the response of tumors from three patients to the JMJD6 inhibitor (11.5mg/kg, intrapertoneally, i.p.), and to FOLFOX (oxaliplatin 12mg/kg, calcium levifolinate 30mg/kg, 5-fluorouracil 55mg/kg, i.p.) or FOLFIRI (irinotecan 40mg/kg, calcium levifolinate 30mg/kg, 5-fluorouracil 55mg/kg, i.p.), as well as to combined usage of JMJD6 inhibitor and FOLFOX or FOLFIRI in PDX models by recording the tumors sizes every 3 or 4 days for 7 times. The differences between groups were analyzed using one-way ANOVA. (i.p. stands for intraperitoneal.).

Results

Compared with FOLFOX or FOLFIRI, WL8 inhibited tumor growth more effectively in the PDX models of three patients (One patient’s partial results are shown in the table). Combinatorial therapies using both JMJD6 and FOLFOX (or FOLFIRI) could further reduced the tumour size.Table: 632P

Group8 Days15 Days22 Days
Control1.8075±0.3950 $^@2.5706±0.2900 #%$^@2.6834±0.0416 #%$^@
FOLFOX1.4184±0.20671.3639±0.2381 *@1.3867±0.4155 *^@
FOLFIRI1.4712±0.15681.3894±0.4543 *@1.7474±0.0705 *$^@
WL80.9656±0.4456 *1.1069±0.4376 *1.1655±0.2884 *%^@
WL8+ FOLFOX0.7125±0.0410 *#%0.7767±0.4359 *0.4833±0.0503 *#%$
WL8+ FOLFIRI1.0325±0.3903*0.6367±0.1436 *#%0.3900±0.0265 *#%$

Relative tumor volumn (on days after first administration, notes: P values are indicated with symbols as follows, * P<0.05 v.s. ctrl; # P<0.05 v.s. FOLFOX; % P<0.05 v.s. FOFIRI; $ P<0.05 v.s. WL8; ^ P<0.05 v.s. WL8+FOLFOX; @ P<0.05 v.s. WL8+FOLFIRI)

Conclusions

We found an small-molecule inhibitor of JMJD6 with impressive therapeutic effects on colorectal cancer in pre-clinical study.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The First Affiliated Hospital of Xiamen University.

Funding

National Natural Science Foundation of China, Fujian Provincial Department of Science and Technology, Fujian Provincial Health and Family Planning Commission Foundation of Youth Scientific Research Project, Xiamen Science and Technology Bureau Foundation of Science and Technology Project for the Benefit of the People.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.